CompletedPhase 2NCT03378531
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency
Studying Argininemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aeglea Biotherapeutics
- Principal Investigator
- Cortney Caudill, LCSWAeglea Biotherapeutics, Inc.
- Intervention
- AEB1102(drug)
- Enrollment
- 14 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2017 – 2022
Study locations (7)
- Stanford University School of Medicine, Stanford, California, United States
- University of Florida, Gainesville, Florida, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- UTSW, Dallas, Texas, United States
- The Hospital for Sick Children, Toronto, Ontario, Canada
- Centro Hospitalar S. Joao, Porto, Portugal
- Great Ormond Street Hospital, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03378531 on ClinicalTrials.gov